Have a feature idea you'd love to see implemented?
Let us know!
DVAX Dynavax Technologies Corp
Price (delayed)
$10.77
Market cap
$1.41B
P/E Ratio
82.85
Dividend/share
N/A
EPS
$0.13
Enterprise value
$1.55B
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
Highlights
DVAX's gross margin is up by 29% YoY and by 2.1% QoQ
Dynavax Technologies's equity has increased by 11% YoY and by 3.9% from the previous quarter
DVAX's EPS has soared by 86% from the previous quarter but it has plunged by 85% YoY
The net income has soared by 86% since the previous quarter but it has dropped by 84% year-on-year
DVAX's quick ratio is down by 21% YoY and by 7% QoQ
Key stats
What are the main financial stats of DVAX
Market
Valuations
Earnings
Shares outstanding
131.04M
Market cap
$1.41B
Enterprise value
$1.55B
Price to earnings (P/E)
82.85
Price to book (P/B)
2.19
Price to sales (P/S)
5.65
EV/EBIT
61.18
EV/EBITDA
46.84
EV/Sales
6.21
Revenue
$249.7M
EBIT
$25.33M
EBITDA
$33.08M
Free cash flow
$36.33M
Per share
Balance sheet
Liquidity
EPS
$0.13
Free cash flow per share
$0.28
Book value per share
$4.91
Revenue per share
$1.91
TBVPS
$7.75
Total assets
$1.02B
Total liabilities
$373.47M
Debt
$250.75M
Equity
$642.85M
Working capital
$819.82M
Debt to equity
0.39
Current ratio
14.18
Quick ratio
12.84
Net debt/EBITDA
4.18
Margins
Efficiency
Dividend
EBITDA margin
13.2%
Gross margin
82%
Net margin
6.9%
Operating margin
-6.4%
Return on assets
1.7%
Return on equity
2.8%
Return on invested capital
2.4%
Return on capital employed
2.7%
Return on sales
10.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DVAX stock price
How has the Dynavax Technologies stock price performed over time
Intraday
-0.92%
1 week
-1.37%
1 month
-0.92%
1 year
-24.63%
YTD
-22.96%
QTD
-3.32%
Financial performance
How have Dynavax Technologies's revenue and profit performed over time
Revenue
$249.7M
Gross profit
$204.83M
Operating income
-$15.95M
Net income
$17.18M
Gross margin
82%
Net margin
6.9%
The company's operating margin has shrunk by 132% YoY but it rose by 38% QoQ
DVAX's operating income has dropped by 118% year-on-year but it is up by 35% since the previous quarter
The net income has soared by 86% since the previous quarter but it has dropped by 84% year-on-year
Dynavax Technologies's net margin has soared by 77% from the previous quarter but it has plunged by 71% YoY
Growth
What is Dynavax Technologies's growth rate over time
Valuation
What is Dynavax Technologies stock price valuation
P/E
82.85
P/B
2.19
P/S
5.65
EV/EBIT
61.18
EV/EBITDA
46.84
EV/Sales
6.21
DVAX's EPS has soared by 86% from the previous quarter but it has plunged by 85% YoY
DVAX's P/B is 80% below its 5-year quarterly average of 10.9 and 19% below its last 4 quarters average of 2.7
Dynavax Technologies's equity has increased by 11% YoY and by 3.9% from the previous quarter
DVAX's revenue is down by 46% year-on-year but it is up by 6% since the previous quarter
The P/S is 20% less than the 5-year quarterly average of 7.1 and 12% less than the last 4 quarters average of 6.4
Efficiency
How efficient is Dynavax Technologies business performance
Dynavax Technologies's ROA has soared by 89% from the previous quarter but it has plunged by 85% YoY
The ROE has soared by 87% from the previous quarter but it has plunged by 86% YoY
Dynavax Technologies's return on invested capital has shrunk by 82% YoY but it has surged by 60% QoQ
DVAX's ROS has soared by 63% from the previous quarter but it has plunged by 61% YoY
Dividends
What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DVAX.
Financial health
How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 172% higher than its total liabilities
DVAX's quick ratio is down by 21% YoY and by 7% QoQ
Dynavax Technologies's current ratio has decreased by 20% YoY and by 7% QoQ
Dynavax Technologies's debt is 61% less than its equity
Dynavax Technologies's equity has increased by 11% YoY and by 3.9% from the previous quarter
The debt to equity has contracted by 11% YoY and by 4.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.